Strategic Pharmacovigilance Activities. Scalable and Tailor-made Outsourcing Models

Webinar: Strategic Pharmacovigilance Activities. Scalable and Tailor-made Outsourcing Models

Larger companies often limit their strategic pharmacovigilance activities outsourcing only to highly manual and repetitive tasks, while the smaller ones may want to outsource their entire pharmacovigilance system. But is there anything in between?

  • How can larger companies benefit from outsourcing strategic pharmacovigilance activities while maintaining full control and compliance?
  • How can small/medium-sized companies get access to a serious pharmacovigilance database that grows with them without having to break the bank?
  • What are the advantages of scalable and tailor-made outsourcing models?
  • How can the pharmaceutical companies obtain benefits from the scalability and standardization required to ensure central oversight while also retaining local effectiveness?

 

You will learn about strategic pharmacovigilance activities outsourcing through scalable and tailor-made outsourcing models and how it can be done in a controlled way:

 

1. Full pharmacovigilance outsourcing

  • What does it mean?
  • How will you remain in control?

2. Outsourcing a pharmacovigilance database

  • How to select a proper database?
  • How to get access to it without buying it yourself?
  • What control levels can you opt for?

3. Outsourcing specific strategic pharmacovigilance activities

  • How to remain in control?

Optimizing your pharmacovigilance activities?

Make use of our experts’ invaluable know-how in managing pharmacovigilance activities while remaining in control.

Who should attend?

  • Global QPPVs / Deputies
  • QPPV Office managers
  • Heads of Pharmacovigilance
  • Heads of Pharmacovigilance Technologies
  • Drug Safety Managers
  • Drug Safety Leaders involved in Risk Management, Aggregate Safety reports, Oversight and Standards

Duration: 50 min.

Speakers:

  • Head of Global Pharmacovigilance, Martijn van de Leur;
  • International QPPV, Olga Asimaki;
  • QPO Manager and Head of Pharmacovigilance Technologies, Gediminas Zvicevičius.
Martijn van de Leur, MSc

Martijn van de Leur, MSc

Head of Global Pharmacovigilance

Other content that might interest you:

Expediting access through Reliance Pathways: MENA region

Expediting access through Reliance Pathways: MENA region

Reliance models are review pathways used by Regulators to expedite the patient access to essential pharmaceutical products and to overcome resource constraints and priorities. Recently, several National Competent Authorities (NCA) in the Middle East North Africa (MENA) region have implemented the Abridged and Verification reviews. These regulatory procedures allow the approvement of needed innovative and/or life-saving drugs.

read more
Medical Device Registration in Russia. Challenges and Issues

Medical Device Registration in Russia. Challenges and Issues

Webinar: Medical Device Registration in Russia. Challenges and Issues The purpose of this webinar is to show the differences and specifics of regulations and law processes that can cause challenges in medical device registration in Russia.   You will learn about:...

read more
eCTD Submission Strategies: In-house vs. Outsourcing

eCTD Submission Strategies: In-house vs. Outsourcing

Webinar: eCTD Submission Different Strategies: In-house vs. Outsourcing eCTD Submission Strategies, including outsourcing, are influenced by varying requirements in various regions and countries. That and diverse technical resources by companies often lead to various...

read more
Building Health Literacy: The Value of Good Writing

Building Health Literacy: The Value of Good Writing

Scientists, doctors, and health authorities often use written communication to present their research, opinions, or guidelines to the patients. While the questions they approach may be complex, the language should not. In medical documents, misinterpreted information may endanger the health and life of a patient. Thus, the main goal in medical writing is to convey the message clearly and concisely to avoid misinterpretation.

read more
Proper Publicizing in CEECs – Path to Successful Social Media Commercials

Proper Publicizing in CEECs – Path to Successful Social Media Commercials

With the growth of social media network users all over the world, there is no doubt that one of the most widely used channels for promoting is social media. Statistics show that Facebook and Instagram were used actively with more than 3.4 billion people daily by January 2020. Therefore, since medical devices and over-the-counter medicines are being more often promoted by commercials on social media nowadays, there is a greater risk of hidden or misleading advertisements.

read more
What do you need to know while preparing RMP for EAEU and CIS region?

What do you need to know while preparing RMP for EAEU and CIS region?

Preparation of Risk Management Plan (RMP) for a specific medicinal product usually is the responsibility of the Qualified Person Responsible for Pharmacovigilance (QPPV) and its team. Thus, QPPVs and their team’s should be familiar with legislation requirements for RMP preparation in different regions. Within this article, we will concentrate on the Eurasian Economic Union (EAEU) and identify specific conditions of EAEU countries as well as to try to understand the expectations of Competent Authorities in this region.

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information